Clinical Efficacy, Safety and Tolerability of Collagenase Clostridium Histolyticum for the Treatment of Peyronie Disease in 2 Large Double-Blind, Randomized, Placebo Controlled Phase 3 Studies
Top Cited Papers
- 1 July 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 190 (1), 199-207
- https://doi.org/10.1016/j.juro.2013.01.087
Abstract
IMPRESS (Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) I and II examined the clinical efficacy and safety of collagenase Clostridium histolyticum intralesional injections in subjects with Peyronie disease. Co-primary outcomes in these identical phase 3 randomized, double-blind, placebo controlled studies included the percent change in the penile curvature abnormality and the change in the Peyronie disease questionnaire symptom bother score from baseline to 52 weeks. IMPRESS I and II examined collagenase C. histolyticum intralesional injections in 417 and 415 subjects, respectively, through a maximum of 4 treatment cycles, each separated by 6 weeks. Men received up to 8 injections of 0.58 mg collagenase C. histolyticum, that is 2 injections per cycle separated by approximately 24 to 72 hours with the second injection of each followed 24 to 72 hours later by penile plaque modeling. Men were stratified by baseline penile curvature (30 to 60 vs 61 to 90 degrees) and randomized to collagenase C. histolyticum or placebo 2:1 in favor of the former. Post hoc meta-analysis of IMPRESS I and II data revealed that men treated with collagenase C. histolyticum showed a mean 34% improvement in penile curvature, representing a mean ± SD -17.0 ± 14.8 degree change per subject, compared with a mean 18.2% improvement in placebo treated men, representing a mean -9.3 ± 13.6 degree change per subject (p <0.0001). The mean change in Peyronie disease symptom bother score was significantly improved in treated men vs men on placebo (-2.8 ± 3.8 vs -1.8 ± 3.5, p = 0.0037). Three serious adverse events (corporeal rupture) were surgically repaired. IMPRESS I and II support the clinical efficacy and safety of collagenase C. histolyticum for the physical and psychological aspects of Peyronie disease.Keywords
This publication has 20 references indexed in Scilit:
- Five-Year Follow-Up of Peyronie’s Graft Surgery: Outcomes and Patient SatisfactionThe Journal of Sexual Medicine, 2011
- The Management of Peyronie’s Disease: Evidence-based 2010 GuidelinesThe Journal of Sexual Medicine, 2010
- Peyronie’s Disease Intervention Trials: Methodological Challenges and IssuesThe Journal of Sexual Medicine, 2009
- Surgical Correction of Peyronie's Disease via Tunica Albuginea Plication or Partial Plaque Excision with Pericardial Graft: Long‐Term Follow UpThe Journal of Sexual Medicine, 2008
- Risk Factors for Emotional and Relationship Problems in Peyronie's DiseaseThe Journal of Sexual Medicine, 2008
- The Chronology of Depression and Distress in Men with Peyronie's DiseaseThe Journal of Sexual Medicine, 2008
- Impact of Peyronie's Disease on Sexual and Psychosocial Functioning: Qualitative Findings in Patients and ControlsThe Journal of Sexual Medicine, 2008
- The Use of Intralesional Clostridial Collagenase Injection Therapy for Peyronie's Disease: A Prospective, Single-Center, Non-Placebo-Controlled StudyThe Journal of Sexual Medicine, 2008
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988
- Limited proteolysis of type I collagen at hyperreactive sites by class I and II Clostridium histolyticum collagenases: complementary digestion patternsBiochemistry, 1987